Antifungal agents for the treatment of systemic mycoses

Seminars in Pediatric Infectious Diseases

Volumn 12, Issue 3, 2001, Pages 246-253

  Schutze, Gordon E ^a  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTACID AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CYCLOSPORIN; CYTARABINE; FLUCONAZOLE; FLUCYTOSINE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; KETOCONAZOLE; OMEPRAZOLE; RIFAMPICIN;

ARTICLE; CANDIDIASIS; CHILL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SOLUBILITY; FEVER; HEADACHE; HUMAN; NAUSEA; NEPHROTOXICITY; SYSTEMIC MYCOSIS; VOMITING;

EID: 0034928865     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/spid.2001.24105     Document Type: Article

References (40)

1. Amphotericin B: 30 Years of clinical experience
2. Amphotericin B-induced oxidative damage and killing of Candida albicans
3. Antifungal agents. Part I. Amphotericin B preparations and flucytosine
4. Liposomal and lipid formulations of amphotericin B: Clinical pharmacokinetics
5. Pharmacokinetics of amphotericin B in children
6. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system
7. Amphotericin B lipid complex therapy of experimental fungal infections in mice
8. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes
9. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary asperillosis
10. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis
11. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis
12. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
13. Clinical use of amphotericin B and derivatives: Lore, mystique, and fact
14. Pretreatment regimens for adverse events related to infusion of amphotericin B
15. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions
16. Use of amphotericin B with azole antifungal drugs: What are we doing?
17. Flucytosine
18. Hepatic reactions during ketoconazole treatment
19. Treatment of systemic fungal infections: Recent progress and current problems
20. High-dose itraconazole in the treatment of severe mycoses
21. Antimicrobial therapy for infants and children: Guidelines for the inpatient and outpatient practice of pediatric infectious diseases
22. Antifungal agents. Part II. The azoles
23. Practice guidelines for the management of cryptococcal disease
24. Cryptococcosis in children with AIDS
25. Practice guidelines for the treatment of candidiasis
26. Candidal meningitis in children with cancer
27. Candidal meningitis in neonates: A 10-year review
28. Practice guidelines for the treatment of coccidioidomycosis
29. Liposomal amphotericin B treatment for neonatal fungal infections
30. Should central venous catheters be removed as soon as candidemia is detected in neonates?
31. Outcome of treatment of candidemia in children whose central catheters were removed or retained
32. Antifungal drugs
33. Candida fungemia in neonates treated with fluconazole: Report of forty cases, including eight with meningitis
34. Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients
35. Prospective multicenter surveillance study of funguria in hospitalized patients
36. The enigma of candiduria: Evolution of bladder irrigation with amphotericin B for management from anecdote to dogma and a lesson from Michiaveli
37. Voriconazole: A new triazole antifungal
38. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida
39. In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species form the Sentry Antimicrobial Surveillance Program in North America and Latin America
40. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis